Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 100

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 100
---
 available when we
need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be required to delay, reduce the
scope of or eliminate one or more of our research or development programs or our commercialization efforts or perhaps even cease the operation
of our business. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional
dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaborations
and licensing arrangements, it may be necessary to relinquish some rights to our technologies or applications or grant licenses on terms
that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if
we do not have an immediate need for additional capital at that time.

20

Off-Balance Sheet Transactions

At September 30, 2025, the Company did not have
any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosure
About Market Risk

As a smaller reporting company, we are not required
to provide the information required by this Item 3.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Form
10-Q, management performed, with the participation of our principal executive officer and principal financial officer, an evaluation of
the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange
Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information
required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within
the time periods specified in the SEC’s forms, and that such information is accumulated and communicated to our management, including
our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the
evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2025, our disclosure controls
and procedures were not effective.

A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented